Patent Law Weblog
recent posts
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
- Supreme Court Oral Argument in Hikma v. Amarin
about
Month: February 2009
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Millennium Pharmaceuticals Inc. et al. v. Teva Parenteral Medicines Inc. et al.1:09-cv-00105; filed February 18, 2009 in the District Court of Delaware…
-
February 23-24, 2009 – Pharmaceutical and Biotech Patent Claim Drafting*** (American Conference Institute) – Palo Alto, CA February 25-26, 2009 – Optimizing Patent Strategies at Patent Forum 2009 (World Research Group) – San Francisco, CA March 2-3, 2009 – 3rd Annual Patent Law Institute (Practising Law Institute) – New York, NY March 3, 2009 –…
-
By Jason Derry* and Donald Zuhn —GPC Biotech and Agennix to Merge GPC Biotech AG and Agennix Inc. have announced a plan to merge. Both companies are focused on discovering and developing treatments for cancer. A new company will be formed with the help of cash from the investment company dievini Hopp Biotech. GPC…
-
American Conference Institute (ACI) will be holding its 3rd Annual Paragraph IV Disputes conference on April 27-28, 2009 in New York, NY. The conference will allow attendees to: • Strategically evaluate patent strength, Orange Book listing, and assertion strategies;• Interpret and apply the MMA statutory scheme as it applies to declaratory judgments;• Litigate with multiple…
-
The Intellectual Property Owners Association (IPO) will be holding its 5th International Judges Conference on Intellectual Property Law on April 20-21, 2009 in Washington, DC. The conference will provide discussions on the following topics: • Litigation Issues: A panel discussion regarding current and possible future judicial collaboration in addressing discovery and settlement issues in cross-border…
-
By Kevin E. Noonan — As we have noted in the past, the World Trade Organization (WTO) and Trade-related Aspects of Intellectual Property Rights (TRIPS) portion of the General Agreements on Tariffs and Trade (GATT) have not resulted in the general reverence for intellectual property protection intended by Western countries in the developing world,…
-
By Donald Zuhn — Last week, Vermillion, Inc. announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for its application directed to diagnostic methods using hepcidin as a biomarker for ovarian cancer. The patent that eventually issues from the allowed application will be the Fremont, CA-based molecular diagnostics company's…
-
By Donald Zuhn — Innovators Looking for Help from Follow-on Biologics Last week, Merck announced that it had acquired Insmed's portfolio of follow-on biologic therapeutic candidates as well as its biologics manufacturing facilities in Boulder, CO (see "Biotech/Pharma Business Briefs"). While the timing and target of the acquisition may have been somewhat surprising, Merck's…
-
By Christopher P. Singer — Recently, the European Patent Office (EPO) published a notice on its website announcing a new fee schedule that will become effective on April 1, 2009. A complete description of the revised fees can be found here. This schedule will be applicable for all EP applications, including divisional and new…
-
By Kevin E. Noonan — Congress has the power, under Article I of the U.S. Constitution, to grant patents "to promote the progress of Science and the Useful Arts." The value of patenting to the public is disclosure –- the raw material that drives progress is full disclosure of an invention in a patent…
Patent Docs 